GTCB Insider Trading Activity and SEC Form 4 Filings
GTCB insider trading summary
No open-market insider purchases or sales of Gtc Biotherapeutics Inc (GTCB) have been reported on SEC Form 4 in the past 12 months.
Latest GTCB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 9, 2010 | Richard A Scotland | Senior VP, Regulatory Affairs | Buy | $16K (14,798 @ $1.08) |
| Jan 19, 2010 | Richard A Scotland | Senior VP, Regulatory Affairs | Sell | $17K (14,798 @ $1.13) |
| Nov 2, 2009 | Biotechnologies S.A.S.U. LFB | Director by Deputization | Buy | $3.6M (3,387,851 @ $1.07) |
| Nov 21, 2008 | Geoffrey F Cox | President, CEO and Chairman | Buy | $7K (43,600 @ $0.17) |
| Nov 21, 2008 | Geoffrey F Cox | President, CEO and Chairman | Buy | $225 (1,500 @ $0.15) |
| Nov 21, 2008 | Geoffrey F Cox | President, CEO and Chairman | Buy | $7K (40,900 @ $0.16) |
| Mar 14, 2008 | Geoffrey F Cox | President, CEO and Chairman | Buy | $6K (12,260 @ $0.50) |
| Mar 14, 2008 | Geoffrey F Cox | President, CEO and Chairman | Buy | $3K (7,400 @ $0.46) |
| Mar 14, 2008 | Geoffrey F Cox | President, CEO and Chairman | Buy | $30K (63,100 @ $0.47) |
| Mar 14, 2008 | Geoffrey F Cox | President, CEO and Chairman | Buy | $2K (3,900 @ $0.49) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.